
Dengue- Pipeline Insight, 2024
Description
Dengue- Pipeline Insight, 2024
DelveInsight’s, “Dengue- Pipeline Insight, 2024,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Dengue pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Dengue: Overview
Dengue is a mosquito-transmitted virus and the leading cause of arthropod-borne viral disease in the world. It is also known as breakbone fever due to the severity of muscle spasms and joint pain, dandy fever, or seven-day fever because of the usual duration of symptoms. Although most cases are asymptomatic, severe illness and death may occur. Aedes mosquitoes transmit the virus and are common in tropical and subtropical parts of the world. The incidence of dengue has increased dramatically over the past few decades, and the infection is now endemic in some parts of the world. A few people who were previously infected with one subspecies of the dengue virus develop severe capillary permeability and bleeding after being infected with another subspecies of the virus. This illness is known as dengue hemorrhagic fever. It is the fastest spreading mosquito-borne viral disease globally, affecting greater than 100 million humans annually. Dengue also causes 20 to 25,000 deaths, primarily in children, and is found in more than 100 countries. Mild symptoms of dengue can be confused with other illnesses that cause fever, aches and pains, or a rash. The most common symptom of dengue is fever with any of the following: Nausea, vomiting, rash, aches and pains (eye pain, typically behind the eyes, muscle, joint, or bone pain). The clinical diagnosis of dengue can be challenging as many other illnesses can present similarly early in the disease course. Other considerations should include malaria, influenza, Zika, chikungunya, measles, and yellow fever. Untreated severe dengue fever may have a mortality rate of 10% to 20%. Appropriate supportive care reduces the mortality rate to roughly 1%. The only way to avoid contracting dengue is to prevent mosquito bites and not travel to endemic areas. There is no specific medicine to treat dengue.
""Dengue- Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Dengue pipeline landscape is provided which includes the disease overview and Dengue treatment guidelines. The assessment part of the report embraces, in depth Dengue commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Dengue collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Dengue R&D. The therapies under development are focused on novel approaches to treat/improve Dengue.
This segment of the Dengue report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Dengue Emerging Drugs
- VIS 513: Visterra
- TAK-003: Takeda
- CDX DENV: Codagenix
- AT 752: Atea Pharmaceuticals
Further product details are provided in the report……..
Dengue: Therapeutic Assessment
This segment of the report provides insights about the different Dengue drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Dengue
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Intra-articular
- Intraocular
- Intrathecal
- Intravenous
- Ophthalmic
- Oral
- Parenteral
- Subcutaneous
- Topical
- Transdermal
- Molecule Type
- Oligonucleotide
- Peptide
- Small molecule
- Product Type
Dengue: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Dengue therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Dengue drugs.
Dengue Report Insights
- Dengue Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Dengue drugs?
- How many Dengue drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Dengue?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Dengue therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Dengue and their status?
- What are the key designations that have been granted to the emerging drugs?
- Visterra
- Takeda
- Codagenix
- Atea Pharmaceuticals
- Abivax
- Janssen Research & Development
- Plex Pharmaceuticals
- VIS 513
- TAK-003
- CDX DENV
- AT 752
- ABX 220
- JNJ-64281802
- TV003
- Research programme: infectious diseases therapeutics
Table of Contents
80 Pages
- Introduction
- Executive Summary
- Dengue: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Dengue– DelveInsight’s Analytical Perspective
- Late Stage Products (Pre-Registration)
- Comparative Analysis
- TAK-003: Takeda
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- Drug Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- AT 752: Atea Pharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- Drug Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Dengue Key Companies
- Dengue Key Products
- Dengue- Unmet Needs
- Dengue- Market Drivers and Barriers
- Dengue- Future Perspectives and Conclusion
- Dengue Analyst Views
- Dengue Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.